VTVT · vTv Therapeutics
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Market Cap
70.97M
52 Wk Range
$17.28 - $44.00
Previous Close
$17.69
Open
$17.54
Volume
2,710
Day Range
$16.89 - $17.68
Enterprise Value
-19.16M
Cash
77.16M
Avg Qtr Burn
-10.19M
Insider Ownership
38.27%
Institutional Own.
43.30%
Qtr Updated
Sep 30th 2026
